Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia

European Journal of Haematology

Volumn 77, Issue 6, 2006, Pages 471-479

  Le, Quoc Hung ^a,b   Thomas, Xavier ^a   Ecochard, René ^b   Iwaz, Jean ^b   Lhéritier, Véronique ^a   Michallet, Mauricette ^a   Fiere, Denis ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Acute lymphoblastic leukaemia; Prognostic factors; Survival; Timed sequential multivariate analysis

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; KARYOTYPE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGE FACTORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 33750617448     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00753.x     Document Type: Article

References (31)

1. EDEN OB, HARRISON G, RICHARDS S, LILLEYMAN JS, BAILEY CC, CHESSELLS JM, HANN IM, HILL FG, GIBSON BE. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia 2000;14:2307-2320.
2. SCHRAPPE M, REITER A, ZIMMERMANN M, HARBOTT J, LUDWIG WD, HENZE G, GADNER H, ODENWALD E, RIEHM H. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000;14:2205-2222.
3. ELLISON RR, MICK R, CUTTNER J et al. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomised clinical trial by Cancer and Leukaemia Group B. J Clin Oncol 1991;9:2002-2015.
4. LARSON RA, DODGE RK, BURNS CP et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995;85:2025-2037.
5. LARSON RA, DODGE RK, LINKER CA et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998;92:1556-1564.
6. DURRANT IJ, RICHARDS SM, PRENTICE HG, GOLDSTONE AH. The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000;14:1327-1352.
7. HOELZER DF. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol Oncol Clin North Am 1993;7:139-160.
8. THOMAS X, DANAILA C, LE QH, SEBBAN C, TRONCY J, CHARRIN C, LHERITIER V, MICHALLET M, MAGAUD JP, FIERE D. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 2001;15:1811-1822.
9. LINKER CA. Risk-adapted treatment of adult acute lymphoblastic leukemia (ALL). Leukemia 1997;11:S24-S27.
10. HOELZER D, THIEL E, LOFFLER H et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123-131.
11. KANTARJIAN HM, WALTERS RS, KEATING MJ et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 1990;8:994-1004.
12. GAYNOR J, CHAPMAN D, LITTLE C et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol 1988;6:1014-1030.
13. MARTIN TG, LINKER CA. Autologous stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am 2001;15:121-143.
14. MARTIN TG, GAJEWSKI JL. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am 2001;15:97-120.
15. BOUCHEIX C, DAVID B, SEBBAN C et al. for the French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). Blood 1994;84:1603-1612.
16. FIERE D, LEPAGE E, SEBBAN C et al. for the French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 1993;11:1990-2001.
17. THIEBAUT A, VERNANT JP, DEGOS L, HUGUET F, REIFFERS J, SEBBAN C, LEPAGE E, THOMAS X, FIERE D. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000;14:1353-1366.
18. HOROWITZ MM, MESSERER D, HOELZER D et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 1991;115:13-18.
19. COX DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
20. COX DR, OAKES D. Analysis of Survival Data. London: Chapman and Hall, 1984.
21. BENNETT JM, CATOVSKY D, DANIEL MT, FLANDRIN G, GALTON DA, GRALNICK HR, SULTAN C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Cooperative Group. Br J Haematol 1976;33:451-458.
22. THOMAS X, BOIRON JM, HUGUET F et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004;22:4075-4086.
23. THERNEAU TM, GRAMBSCH PM. Modeling Survival Data: Extending the Cox Model. New York: Springer-Verlag, 2000.
24. BACCARANI M, CORBELLI G, AMADORI S, DRENTHE-SCHONK A, WILLEMZE R, MELONI G, CARDOZO PL, HAANEN C, MANDELLI F, TURA S. Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patients. Blood 1982;60:677-684.
25. TAKEUCHI J, KYO T, NAITO K et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002;16:1259-1266.
26. KANTARJIAN HM, O'BRIEN S, SMITH TL et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547-561.
27. HUSSEIN KK, DAHLBERG S, HEAD D, WADDELL CC, DABICH L, WEICK JK, MORRISON F, SAIKI JH, METZ E, RIVKIN SE. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989;73:57-63.
28. ROHATINER AZ, BASSAN R, BATTISTA R, BARNETT MJ, GREGORY W, LIM J, AMESS J, OZA A, BARBUI T, HORTON M. High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukaemia. Br J Cancer 1990;62:454-458.
29. CHARRIN C. Cytogenetic abnormalities in adult acute lymphoblastic leukaemia: correlations with hematologic findings outcome. A Collaborative Study of the Groupe Français de Cytogénétique Hématologique. Blood 1996;87:3135-3142.
30. FADERL S, KANTARJIAN HM, TALPAZ M, ESTROV Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998;91; 3995-4019.
31. WETZLER M, DODGE RK, MROZEK K et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood 1999;93:3983-3993.